Jazz Pharmaceuticals plc JAZZ
4 trading plans running, 54 Form 144 notices for $104.4M
10-Q, 10-K and Form 144What JAZZ's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Jun 2, 2023 to Aug 5, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Mark D. Smith Director |
Ended 10b5-1 plan | Jun 15, 2026 | 10-Q Aug 3, 2026 | ||
| Renee D. Gala President and Chief Executive Officer |
Adopted 10b5-1 plan | Jun 4, 2026 | 10-Q Aug 3, 2026 | ||
| Robert Iannone Executive Vice President, Global Head of Research and Development, Chief Medical Officer |
Adopted 10b5-1 plan | May 28, 2026 | 10-Q Aug 3, 2026 | ||
| Mark D. Smith Director |
Adopted 10b5-1 plan | Mar 9, 2026 | 10-Q May 5, 2026 | ||
| Neena M. Patil Executive Vice President and Chief Legal Officer |
Adopted 10b5-1 plan | Feb 26, 2026 | 10-Q May 5, 2026 | ||
| Bruce C. Cozadd Chairman |
Adopted 10b5-1 plan | Nov 26, 2025 | 10-K Feb 24, 2026 | ||
What the company wroteThe following is a summary of the material terms of the contracts, instructions or written plans for the purchase or sale of the company’s securities adopted or terminated by our officers (as defined in Rule 16a-1(f) under the Exchange Act) and directors during the quarter ended December 31, 2025: Type of Trading Arrangement Name and Position Date Action Rule 10b5-1* Expiration Date Total Ordinary Shares to be Sold Bruce C. Cozadd (Chairman) 11/26/2025 Adoption X 2/26/2027 Up to 72,000 * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. | |||||
| Robert Iannone Executive Vice President, Global Head of Research and Development, Chief Medical Officer |
Ended 10b5-1 plan | Dec 6, 2024 | 10-K Feb 26, 2025 | ||
| Bruce Cozadd Chairman and Chief Executive Officer |
Adopted 10b5-1 plan | Jun 5, 2024 | 10-Q Aug 1, 2024 | ||
| Robert Iannone Executive Vice President, Global Head of Research and Development |
Adopted plan | Mar 7, 2024 | 10-Q May 2, 2024 | ||
What the company wroteThe following is a summary of the material terms of the contracts, instructions or written plans for the purchase or sale of the Company’s securities adopted or terminated by our officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) and directors during the quarter ended March 31, 2024: Type of Trading Arrangement Name and Position Date Action Rule 10b5-1* Expiration Date Total Ordinary Shares to be Sold Robert Iannone March 7, 2024 Modification X March 7, 2025 10,681 Executive Vice President, Global Head of Research and Development * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. | |||||
| Robert Iannone Executive Vice President Global Head of Research and Development |
Ended 10b5-1 plan | Aug 18, 2023 | 10-Q Nov 8, 2023 | ||
| Bruce C. Cozadd Chairman and Chief Executive Officer |
Adopted 10b5-1 plan | Aug 14, 2023 | 10-Q Nov 8, 2023 | ||
| Neena M. Patil Executive Vice President and Chief Legal Officer |
Adopted 10b5-1 plan | Jun 2, 2023 | 10-Q Aug 9, 2023 | ||
Show the other 4 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 19 filings checked since May 1, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 6, 2026 | BRUCE COZADD Director |
68,808 | $16.2M |
| Nov 4, 2026 | PATRICIA CARR Officer |
1,413 | $327K |
| Nov 3, 2026 | RENEE D GALA Officer, Director |
1,000 | $225K |
| Nov 2, 2026 | Bruce C Cozadd Officer |
6,000 | $1.3M |
| Oct 8, 2026 | ANNE O'RIORDAN Director |
14,687 | $3.4M |
| Oct 6, 2026 | RENEE D GALA Officer |
2,000 | $473K |
| Oct 1, 2026 | Bruce C Cozadd Officer |
6,000 | $1.4M |
| Sep 10, 2026 | NEENA PATIL Officer |
1,200 | $289K |
| Sep 8, 2026 | Henderson Mary Elizabeth Director |
2,691 | $664K |
| Sep 8, 2026 | RENEE D GALA Officer |
2,000 | $486K |
| Sep 1, 2026 | Bruce C Cozadd Officer |
6,000 | $1.5M |
| Aug 31, 2026 | Kennedy Patrick Director |
3,507 | $858K |
| Aug 31, 2026 | Henderson Mary Elizabeth Director |
3,852 | $942K |
| Aug 31, 2026 | Smith Mark Douglas Director |
3,507 | $858K |
| Aug 31, 2026 | Cook Jennifer E. Director |
3,507 | $858K |
| Aug 31, 2026 | Hamill Laura Director |
3,507 | $858K |
| Aug 31, 2026 | McSharry Heather Ann Director |
3,507 | $858K |
| Aug 31, 2026 | Winningham Rick E Director |
3,507 | $858K |
| Aug 31, 2026 | ENRIGHT PATRICK G Director |
3,507 | $858K |
| Aug 31, 2026 | COZADD BRUCE C Director |
2,506 | $613K |
| Aug 31, 2026 | LOVE TED W Director |
1,527 | $373K |
| Aug 31, 2026 | RIEDEL NORBERT G Director |
3,507 | $858K |
| Aug 27, 2026 | ROBERT IANNONE Officer |
76,921 | $19.2M |
| Aug 7, 2026 | ORiordan Anne Director |
3,507 | $882K |
| Aug 3, 2026 | Bruce C Cozadd Officer |
6,000 | $1.5M |
| Jul 1, 2026 | Bruce C Cozadd Officer |
6,000 | $1.4M |
| Jun 15, 2026 | MARK D SMITH Director |
1,157 | $267K |
| Jun 10, 2026 | NEENA PATIL Officer |
1,200 | $278K |
| Jun 1, 2026 | Bruce C Cozadd Officer |
6,000 | $1.4M |
| May 28, 2026 | NEENA PATIL Officer |
1,192 | $282K |
| May 28, 2026 | SAMANTHA PEARCE Officer |
6,907 | $1.6M |
| May 22, 2026 | HEATHER MCSHARRY Director |
2,000 | $482K |
| May 22, 2026 | RICK WINNINGHAM Director |
2,741 | $662K |
| May 1, 2026 | Bruce C Cozadd Officer |
6,000 | $1.2M |
| Apr 1, 2026 | Bruce C Cozadd Officer |
6,000 | $1.1M |
| Mar 9, 2026 | PATRICIA CARR Officer |
1,287 | $235K |
| Mar 5, 2026 | Henderson Mary Elizabeth Officer |
2,643 | $499K |
| Mar 5, 2026 | Carr Patricia Officer |
2,723 | $514K |
| Mar 3, 2026 | Bruce C Cozadd Officer |
6,000 | $1.1M |
| Feb 27, 2026 | PATRICIA CARR Officer |
1,117 | $213K |
| Feb 27, 2026 | NORBERT RIEDEL Director |
3,415 | $656K |
| Feb 26, 2026 | Henderson Mary Elizabeth Officer |
10,116 | $2.0M |
| Feb 26, 2026 | NEENA PATIL Officer |
55,600 | $10.7M |
| Feb 26, 2026 | Carr Patricia Officer |
2,370 | $466K |
| Dec 9, 2025 | MARY ELIZABETH HENDERSON Officer |
2,238 | $379K |
| Dec 5, 2025 | PATRICIA CARR Officer |
4,660 | $798K |
| Dec 1, 2025 | O'Keefe Kenneth W Director |
1,249 | $221K |
| Nov 26, 2025 | BRUCE COZADD Director |
77,500 | $13.8M |
| Nov 20, 2025 | HEATHER MCSHARRY Director |
3,415 | $607K |
| Nov 19, 2025 | Henderson Mary Elizabeth Officer |
2,961 | $377K |
| Nov 18, 2025 | RICK WINNINGHAM Director |
5,500 | $995K |
| Nov 18, 2025 | PATRICIA CARR Officer |
5,319 | $968K |
| Nov 18, 2025 | Bruce C Cozadd Officer |
18,000 | $3.3M |
| Nov 17, 2025 | ROBERT IANNONE Officer |
7,159 | $1.2M |
Show the other 46 notices
From the Form 144 XML filed with the SEC, since Nov 17, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/JAZZ/export.csv") into a cell.